Ahrends Tomasz, Borst Jannie
Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Immunology. 2018 Apr 27;154(4):582-92. doi: 10.1111/imm.12941.
Cancer immunotherapy focuses mainly on anti-tumour activity of CD8 cytotoxic T lymphocytes (CTLs). CTLs can directly kill all tumour cell types, provided they carry recognizable antigens. However, CD4 T cells also play important roles in anti-tumour immunity. CD4 T cells can either suppress or promote the anti-tumour CTL response, either in secondary lymphoid organs or in the tumour. In this review, we highlight opposing mechanisms of conventional and regulatory T cells at both sites. We outline how current cancer immunotherapy strategies affect both subsets and how selective modulation of each subset is important to maximize the clinical response of cancer patients.
癌症免疫疗法主要聚焦于CD8细胞毒性T淋巴细胞（CTL）的抗肿瘤活性。只要肿瘤细胞携带可识别的抗原，CTL就能直接杀死所有类型的肿瘤细胞。然而，CD4 T细胞在抗肿瘤免疫中也发挥着重要作用。CD4 T细胞在次级淋巴器官或肿瘤中既可以抑制也可以促进抗肿瘤CTL反应。在本综述中，我们着重介绍了传统T细胞和调节性T细胞在这两个部位的相反作用机制。我们概述了当前的癌症免疫疗法策略如何影响这两个亚群，以及对每个亚群进行选择性调节对于最大化癌症患者的临床反应为何至关重要。
